This well-designed 2002 rat study (five protocols; 12 Sprague-Dawley and 11 Munich-Wistar rats plus adrenalectomized controls) used semiquantitative immunoblotting and immunoperoxidase/confocal microscopy to test which aldosterone effects on renal Na transporters depend on the classical mineralocorticoid receptor (MR) . Spironolactone left pre-macula densa transporters unchanged (NHE3 107±13, NKCC2 81±8) but reduced NCC to 58±7% and the 70-kDa γ-ENaC form to 60±6% (P<0.05); α-ENaC fell to 56±9% in whole-kidney blots .
The key finding: despite dose >10-fold the 95% MR-blockade threshold, and confirmed efficacy (elevated serum K, blocked α-ENaC upregulation in NaCl-restricted vs replete rats), spironolactone did NOT prevent the apical redistribution of ENaC in connecting tubule cells during NaCl restriction—confirmed by blinded rank-sum analysis across all three ENaC subunits . Aldosterone infusion in dexamethasone-replaced adrenalectomized rats raised NCC ~7.5-fold (748±88 vs 100±29), confirming NCC is MR-regulated, and transcript-level data cited by the authors indicate the NCC protein effect is indirect (no mRNA change) .
Strengths: mechanistic pharmacology with physiological validation (serum K 6.0±0.2 vs 4.2±0.2 mM; elevated aldosterone 899±102 vs 565±27 nM indicating volume contraction), dose validation, blinded trafficking assessment. Weaknesses: small n (6–12 per group), whole-kidney homogenates cannot distinguish DCT1 vs DCT2 NCC regulation (acknowledged by authors); volume contraction induced by the drug is a confounder; rat-only design limits human extrapolation . Clinically, later registry data in unselected heart failure populations found no mortality benefit of spironolactone after propensity adjustment (HR 1.05, 95% CI 1.00–1.11), tempering the mechanistic enthusiasm tied to RALES . Overall: rigorous, mechanistically decisive for its question; the MR-independent ENaC trafficking result remains the most cited insight.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.